Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: SORAFENIB - , . Treffer: 9
2018
Li, M; Su, Y; Zhang, F; Chen, K; Xu, X; Xu, L; Zhou, J; Wang, W
A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Acta Biomater. 2018; 75(10):413-426
Doi: 10.1016/j.actbio.2018.05.049
Web of Science
PubMed
FullText
FullText_MUG
2017
Bettinger, D; Spode, R; Glaser, N; Buettner, N; Boettler, T; Neumann-Haefelin, C; Brunner, TB; Gkika, E; Maruschke, L; Thimme, R; Schultheiss, M
Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
BMC Gastroenterol. 2017; 17(1):98
Doi: 10.1186/s12876-017-0656-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Ganten, TM; Stauber, RE; Schott, E; Malfertheiner, P; Buder, R; Galle, PR; Göhler, T; Walther, M; Koschny, R; Gerken, G
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Clin Cancer Res. 2017; 23(19):5720-5728
Doi: 10.1158/1078-0432.CCR-16-0919
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Pehserl, AM; Ress, AL; Stanzer, S; Resel, M; Karbiener, M; Stadelmeyer, E; Stiegelbauer, V; Gerger, A; Mayr, C; Scheideler, M; Hutterer, GC; Bauernhofer, T; Kiesslich, T; Pichler, M
Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Int J Mol Sci. 2016; 17(12):
Doi: 10.3390/ijms17122011
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
Lindner, C; Dierneder, J; Pall, G; Pirich, C; Hoffmann, M; Raderer, M; Becherer, A; Niederle, B; Lipp, R; Lind, P; Gallowitsch, H; Romeder, F; Virgolini, I
[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Nuklearmedizin. 2015; 54(3):125-130
Doi: 10.3413/Nukmed-0688-14-07
Web of Science
PubMed
FullText
FullText_MUG
Schultheiß, M; Bettinger, D; Neeff, HP; Brunner, TB; Thimme, R
[Hepatocellular Carcinoma: therapeutic options 2015].
Dtsch Med Wochenschr. 2015; 140(14):1063-8
Doi: 10.1055/s-0041-102333
Web of Science
PubMed
FullText
FullText_MUG
2014
Herz, C; Hertrampf, A; Zimmermann, S; Stetter, N; Wagner, M; Kleinhans, C; Erlacher, M; Schüler, J; Platz, S; Rohn, S; Mersch-Sundermann, V; Lamy, E
The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC.
J Cell Mol Med. 2014; 18(12): 2393-2403.
Doi: 10.1111/jcmm.12412
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Walter, I; Wolfesberger, B; Miller, I; Mair, G; Burger, S; Gallè, B; Steinborn, R
Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
Oncol Rep. 2014; 31(3):1147-1156
Doi: 10.3892/or.2013.2954
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2013
Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Kilian, K; Garbe, C; Egberts, F; Poppe, LM; Hauschild, A; Gutzmer, R
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
J Dtsch Dermatol Ges. 2013; 11(9):846-853
Doi: 10.1111/ddg.12100
Web of Science
PubMed
FullText
FullText_MUG